Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Published version of a preprint
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Most patients with late-stage high-grade serous ovarian cancer (HGSOC) initially respond to chemotherapy but inevitably relapse and develop resistance, highlighting the need for novel therapies to improve patient outcomes. The MEK/ERK pathway is activated in a large subset of HGSOC, making it an attractive therapeutic target. Here, we systematically evaluated the extent of MEK/ERK pathway activation and efficacy of pathway inhibition in a large panel of well-annotated HGSOC patient–derived xenograft models. The vast majority of models were nonresponsive to the MEK inhibitor cobimetinib (GDC-0973) despite effective pathway inhibition. Proteomic analyses of adaptive responses to GDC-0973 revealed that GDC-0973 upregulated the proapoptotic protein BIM, thus priming the cells for apoptosis regulated by BCL2-family proteins. Indeed, combination of both MEK inhibitor and dual BCL-2/XL inhibitor (ABT-263) significantly reduced cell number, increased cell death, and displayed synergy in vitro in most models. In vivo, GDC-0973 and ABT-263 combination was well tolerated and resulted in greater tumor growth inhibition than single agents. Detailed proteomic and correlation analyses identified two subsets of responsive models—those with high BIM at baseline that was increased with MEK inhibition and those with low basal BIM and high pERK levels. Models with low BIM and low pERK were nonresponsive. Our findings demonstrate that combined MEK and BCL-2/XL inhibition has therapeutic activity in HGSOC models and provide a mechanistic rationale for the clinical evaluation of this drug combination as well as the assessment of the extent to which BIM and/or pERK levels predict drug combination effectiveness in chemoresistant HGSOC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intriguingly, in high-grade serous ovarian cancers (HGSOC), we have also found that HGSOC patient-derived xenograft models that show strong ERK-pathway activation respond to MEK inhibition with upregulation of BIM, a pro-apoptotic target of BCL-xL, and that dual inhibition with navitoclax enhances the efficacy of MEK inhibitors in most models (19), only one of which contained a KRAS mutation;”
From Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors (2024) · cites this paper as [19]
In the citing paper
“Intriguingly, in high-grade serous ovarian cancers (HGSOC), we have also found that HGSOC patient-derived xenograft models that show strong ERK-pathway activation respond to MEK inhibition with upregulation of BIM, a pro-apoptotic target of BCL-xL, and that dual inhibition with navitoclax enhances the efficacy of MEK inhibitors in most models (19), only one of which contained a KRAS mutation;”
From Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors (2024) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Self-citationDuncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619 · cited 1×
“BIM represents a critical regulator of apoptosis induced by a variety of targeted therapies in both hematologic and solid tumors, including ovarian cancer, as previously demonstrated by our group and others (58).”
BackgroundMEK1 and MEK2 inhibitors and cancer therapy: the long and winding road
Caunt, C. J., Sale, M. J., Smith, P. D., & Cook, S. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4000 · Cited by 606 · cited 1×
“The most upregulated phosphoprotein was MEK, consistent with inhibition of its catalytic activity, its phosphorylation by RAF proteins, and activation of feedback loops (37).”
BackgroundGandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603 · cited 1×
“The oral BCL-2/XL dual inhibitor ABT-263 (navitoclax) exhibits an acceptable safety profile in clinical trials of patients with solid tumors, with dosedependent thrombocytopenia as the major adverse effect (56).”
BackgroundThe Genomic Landscape of Response to EGFR Blockade in Colorectal Cancer
Bertotti, A., Papp, E., Jones, S., Adleff, V., Anagnostou, V., Lupo, B., Sausen, M., Phallen, J., Hruban, C. A., Tokheim, C., et al. (2015) · Nature · doi:10.1038/nature14969 · Cited by 479 · cited 1×
“Genomic sequencing of the PDX models, including sample library construction, targeted capture, nextgeneration sequencing, and bioinformatics analyses were performed as previously described (27, 30, 31).”
MethodSelf-citationLuciano, F., Jacquel, A., Colosetti, P., Herrant, M., Cagnol, S., Pages, G., & Auberger, P. (2003) · Oncogene · doi:10.1038/sj.onc.1206792 · Cited by 477 · cited 1×
“Activated ERK1/2 phosphorylates BIM on serine 69, leading to its ubiquitination and degradation (38, 39).”
BackgroundCorcoran, R. B., Cheng, K. A., Hata, A. N., Faber, A. C., Ebi, H., Coffee, E. M., Greninger, P., Brown, R. D., Godfrey, J. T., Cohoon, T. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.11.007 · Cited by 377
Research works printed but not linked: 41
- Siegel, 2019, Cancer statistics, 2019, A Cancer J Clin, 69, 7, 10.3322/caac.21551 · DOI · Paper page
- Berns, 2012, The changing view of high-grade serous ovarian cancer, Cancer Res, 72, 2701, 10.1158/0008-5472.CAN-11-3911 · DOI · Paper page
- Bowtell, 2015, Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer, Nat Rev Cancer, 15, 668, 10.1038/nrc4019 · DOI · Paper page
- Bell, 2011, Integrated genomic analyses of ovarian carcinoma, Nature, 474, 609, 10.1038/nature10166 · DOI · Paper page
- Patch, 2015, Whole-genome characterization of chemoresistant ovarian cancer, Nature, 521, 489, 10.1038/nature14410 · DOI · Paper page
- Akbani, 2014, A pan-cancer proteomic perspective on The Cancer Genome Atlas, Nat Commun, 5, 3887, 10.1038/ncomms4887 · DOI · Paper page
- Li, 2013, TCPA: a resource for cancer functional proteomics data, Nat Methods, 10, 1046, 10.1038/nmeth.2650 · DOI · Paper page
- Yap, 2013, Development of therapeutic combinations targeting major cancer signaling pathways, J Clin Oncol, 31, 1592, 10.1200/JCO.2011.37.6418 · DOI · Paper page
- Liu, 2014, New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances, Clin Cancer Res, 20, 5150, 10.1158/1078-0432.CCR-14-1312 · DOI · Paper page
- Liu, 2014, Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study, Lancet Oncol, 15, 1207, 10.1016/S1470-2045(14)70391-2 · DOI · Paper page
- Kim, 2017, Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant ovarian cancer models, Clin Cancer Res, 23, 3097, 10.1158/1078-0432.CCR-16-2273 · DOI · Paper page
- Matulonis, 2017, Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer, Ann Oncol, 28, 512, 10.1093/annonc/mdw672 · DOI · Paper page
- Holohan, 2013, Cancer drug resistance: an evolving paradigm, Nat Rev Cancer, 13, 714, 10.1038/nrc3599 · DOI · Paper page
- Schwarz, 2015, Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis, PLoS Med, 12, e1001789, 10.1371/journal.pmed.1001789 · DOI · Paper page
- Hew, 2016, MAPK activation predicts poor outcome and the MEK inhibitor, selumetinib, reverses antiestrogen resistance in ER-positive high-grade serous ovarian cancer, Clin Cancer Res, 22, 935, 10.1158/1078-0432.CCR-15-0534 · DOI
- Zhang, 2016, Integrated proteogenomic characterization of human high-grade serous ovarian cancer, Cell, 166, 755, 10.1016/j.cell.2016.05.069 · DOI · Paper page
- Macintyre, 2018, Copy-number signatures and mutational processes in ovarian carcinoma, biorxiv, 50, 1262
- Zhao, 2014, The clinical development of MEK inhibitors, Nat Rev Clin Oncol, 11, 385, 10.1038/nrclinonc.2014.83 · DOI · Paper page
- Miller, 2014, MEK1/2 inhibitors in the treatment of gynecologic malignancies, Gynecol Oncol, 133, 128, 10.1016/j.ygyno.2014.01.008 · DOI
- Pepa Della, 2015, Low grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy, Cancer Treat Rev, 41, 136, 10.1016/j.ctrv.2014.12.003 · DOI
- Okumura, 2014, Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers, Clin Cancer Res, 20, 4193, 10.1158/1078-0432.CCR-13-2365 · DOI · Paper page
- Farley, 2013, Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study, Lancet Oncol, 14, 134, 10.1016/S1470-2045(12)70572-7 · DOI · Paper page
- Domcke, 2013, Evaluating cell lines as tumour models by comparison of genomic profiles, Nat Commun, 4, 2126, 10.1038/ncomms3126 · DOI · Paper page
- George, 2017, A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers, JCI Insight, 2, e89760, 10.1172/jci.insight.89760 · DOI · Paper page
- Zervantonakis, 2017, Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response, Nat Commun, 8, 365, 10.1038/s41467-017-00263-7 · DOI
- Jones, 2015, Personalized genomic analyses for cancer mutation discovery and interpretation, Sci Transl Med, 7, 283ra53, 10.1126/scitranslmed.aaa7161 · DOI · Paper page
- Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, 371, 1867, 10.1056/NEJMoa1408868 · DOI · Paper page
- Ascierto, 2016, Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial, Lancet Oncol, 17, 1248, 10.1016/S1470-2045(16)30122-X · DOI · Paper page
- Choo, 2012, Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions, Drug Metab Dispos, 40, 919, 10.1124/dmd.111.043778 · DOI
- Ley, 2003, Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim, J Biol Chem, 278, 18811, 10.1074/jbc.M301010200 · DOI · Paper page
- Yang, 2008, ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation, Nat Cell Biol, 10, 138, 10.1038/ncb1676 · DOI · Paper page
- Oltersdorf, 2005, An inhibitor of Bcl-2 family proteins induces regression of solid tumours, Nature, 435, 677, 10.1038/nature03579 · DOI · Paper page
- Park, 2008, Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins, J Med Chem, 51, 6902, 10.1021/jm800669s · DOI · Paper page
- Bendell, 2017, A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor, Br J Cancer, 116, 575, 10.1038/bjc.2017.10 · DOI · Paper page
- Greco, 1995, The search for synergy: a critical review from a response surface perspective, Pharmacol Rev, 47, 331
- Lehár, 2008, Combination chemical genetics, Nat Chem Biol, 4, 674, 10.1038/nchembio.120 · DOI · Paper page
- Tan, 2013, Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models, Mol Cancer Ther, 12, 853, 10.1158/1535-7163.MCT-12-0949 · DOI · Paper page
- Sun, 2017, Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers, Sci Transl Med, 9, eaal5148, 10.1126/scitranslmed.aal5148 · DOI · Paper page
- Engelman, 2008, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers, Nat Med, 14, 1351, 10.1038/nm.1890 · DOI · Paper page
- Tolcher, 2015, Antitumor activity in RAS-driven tumors by blocking AKT and MEK, Clin Cancer Res, 21, 739, 10.1158/1078-0432.CCR-14-1901 · DOI · Paper page
- Lheureux, 2015, Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma, Int J Cancer, 136, E340, 10.1002/ijc.29104 · DOI
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer
Labrie, M., Brugge, J. S., Mills, G. B., & Zervantonakis, I. K. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00454-5 · Cited by 369
Self-citationStover, E. H., Baco, M. B., Cohen, O., Li, Y. Y., Christie, E. L., Bagul, M., Goodale, A., Lee, Y., Pantel, S., Rees, M. G., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1243 · Cited by 49
“40), and BCL-2/BCL-XL inhibitors ABT-263 and ABT-737 also synergize with several other targeted agents in HGSOC cell lines, including the CDK inhibitor dinaciclib (41), PI3K/mTOR inhibitors (16, 42), and MEK inhibitors (43).”
BackgroundSelf-citationCorcoran, R. B., Do, K. T., Kim, J. E., Cleary, J. M., Parikh, A. R., Yeku, O. O., Xiong, N., Weekes, C. D., Veneris, J., Ahronian, L. G., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3135 · Cited by 46
Self-citationBecker, J. H., Metropulos, A. E., Spaulding, C., Marinelarena, A. M., Shields, M. A., Principe, D. R., Pham, T. D., & Munshi, H. G. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3574 · Cited by 17
Metadata
- Authors
- Iavarone, C., Zervantonakis, I. K., Selfors, L. M., Palakurthi, S., Liu, J. F., Drapkin, R., Matulonis, U. A., Hallberg, D., Velculescu, V. E., Leverson, J. D., Sampath, D., Mills, G. B., & Brugge, J. S.
- Affiliations
- 1Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, Massachusetts.
- 2Belfer Institute for Applied Cancer Res, Dana-Farber Cancer Institute, Boston, Massachusetts.
- 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- 4Penn Ovarian Cancer Res Center, Department of Obstetrics and Gynecology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
- 5The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- 6Oncology Development, AbbVie, Inc., North Chicago, Illinois.
- 7Translational Oncology, Genentech, South San Francisco, California.
- 8Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2019-03-01
- Volume
- 18
- Issue
- 3
- Pages
- 642-655
- ISSN
- 1535-7163
- 1538-8514
- Cited by
- 52
- References
- 17
- Language
- en
- Funders
- Dr. Miriam and Sheldon G. Adelson Medical Research FoundationDr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)
- Breast Cancer Research FoundationBreast Cancer Research Foundation (BCRF)
- Ovarian Cancer Research Fund Alliance
- HHS | National Institutes of HealthHHS | National Institutes of Health (NIH) (CA121113)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. https://app.cochat.ai/papers/10.1158/1535-7163.mct-18-0413
- The paper
- Iavarone, C., Zervantonakis, I. K., Selfors, L. M., Palakurthi, S., Liu, J. F., Drapkin, R., Matulonis, U. A., Hallberg, D., Velculescu, V. E., Leverson, J. D., Sampath, D., Mills, G. B., & Brugge, J. S. (2019). Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-18-0413
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.